D&D Pharmatech (XKRX:347850) Debt-to-EBITDA : 1.41 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

D&D Pharmatech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩3,014 Mil. D&D Pharmatech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩5,121 Mil. D&D Pharmatech's annualized EBITDA for the quarter that ended in Dec. 2023 was ₩5,790 Mil. D&D Pharmatech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.40.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for D&D Pharmatech's Debt-to-EBITDA or its related term are showing as below:

XKRX:347850' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.74 Med: -0.06 Max: 5.62
Current: 5.62

During the past 6 years, the highest Debt-to-EBITDA Ratio of D&D Pharmatech was 5.62. The lowest was -0.74. And the median was -0.06.

XKRX:347850's Debt-to-EBITDA is ranked worse than
82.96% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs XKRX:347850: 5.62

D&D Pharmatech Debt-to-EBITDA Historical Data

The historical data trend for D&D Pharmatech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech Debt-to-EBITDA Chart

D&D Pharmatech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

0.19

-0.12

-0.74

-0.19

0.79

D&D Pharmatech Quarterly Data
	Dec22	Sep23	Dec23
Debt-to-EBITDA	-0.06	N/A	1.41

Competitive Comparison of D&D Pharmatech's Debt-to-EBITDA

For the Biotechnology subindustry, D&D Pharmatech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

D&D Pharmatech's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D&D Pharmatech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where D&D Pharmatech's Debt-to-EBITDA falls into.

D&D Pharmatech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

D&D Pharmatech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3013.681	+	5120.622)	/	10349.673
	=	0.79

D&D Pharmatech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3013.681	+	5120.622)	/	5789.952
	=	1.40

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

D&D Pharmatech (XKRX:347850) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

D&D Pharmatech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech (XKRX:347850) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR

Website

http://www.ddpharmatech.com

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech (XKRX:347850) Headlines

No Headlines